# Data Sheet (Cat.No.T10963)



# Dazopride

### **Chemical Properties**


CAS No.: 70181-03-2

Formula: C15H23ClN4O2

Molecular Weight: 326.82

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



## **Biological Description**

Description	Dazopride is an antiemetic agent.			
Targets(IC50)	Others			
In vivo	Dasopride (0.3 mg / kg) can significantly enhance gastric emptying. In the gastric emptying test, its efficacy is about six times higher than that of metoclopramide.  Dazopril (0.3-10.0 mg / kg, intravenous) produced dose-related increases in anal motility mainly by increasing the anal contraction amplitude in three sober dogs.  Dazopril significantly reduced the frequency of vomiting in the control group. Doxolipril (5 mg / kg, intraperitoneal injection) antagonizes tetralin induced vomiting, but not			
	0.25-2.5 mg / kg. Although larger doses of 1.0 mg / kg eliminated or weakened its response, dazopril could not change cisplatin-induced vomiting at 0.1 mg / kg (iv), while dazopride at 5.0 mg / kg antagonized vomiting in all animals development of.			

### **Preparing Stock Solutions**

	1mg	5mg	10mg
1 mM	3.0598 mL	15.2989 mL	30.5979 mL
5 mM	0.612 mL	3.0598 mL	6.1196 mL
10 mM	0.306 mL	1.5299 mL	3.0598 mL
50 mM	0.0612 mL	0.306 mL	0.612 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

#### Reference

Alphin RS, et al. Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility. Dig Dis Sci. 1986 May;31(5):524-9.

Page 1 of 2 www.targetmol.com



Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com